Purchase this article with an account.
Gerhard Kieselbach, Claus Zehetner, martina kralinger, inga waltl, anna vavrovsky; Retrospective analysis of intravitreal incections for age related macular degeneration (ARMD) from 2012 to 2016. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2395.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate outcome of anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related macular degeneration (ARMD) in the real-life setting and to compare number of injections per year with visual acuity at baseline and four years after injections administered by physicians.
Retrospective, single-centre study. Medical records of patients receiving anti-VEGF treatment for ARMD between 2012 and 2016 were evaluated. Outcome measures were baseline visual acuity (VA), change in VA and number of intravitreal injections per eye.
For this study 1876 patients receiving intravitreal injections between 2012 and 2016 were identified. The records of 1156 patients were evaluated for this study. 1156 patients received a total of 13 127 intravitreal anti-VEGF injections over four years. 28 % of patients received treatment for both eyes. VA was obtained in 654 eyes, which were treated for four years. The mean baseline VA was 0.32. The mean change of VA from baseline was -2 letters and the mean numbers of injections were 4.7 and 4.1 at years 1 and year 2, respectively. There was a positive correlation between change of VA and number of injections per eye. However, more than 40% had VA of 0.32 or better.
Real life data show not more than 15% of patients with ARMD receiving 6 ore more injections per year. Mean injections per year and eye were 4.4 for right eyes and 3.2 for left eyes. Patients receiving injections for both eyes had higher numbers of injections than patients treated for one eye. VA could be maintained in one third of all patients.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only